Genomic instability is one of the most pervasive characteristics of tumour cells and is probably the combined effect of DNA damage, tumour-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells. Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities. A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Boveri, T. Zur Frage der Entstehung Maligner Tumoren (Gustav Fischer, 1914).
Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J. Cell Sci. 121, 1–84 (2008). A translation of Boveri's original work that proposed the hypothesis that a form of genomic dysregulation characterizes tumour cells.
Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010).
Hoeijmakers, J. H. DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475–1485 (2009).
Phillips, D. H., Hewer, A., Martin, C. N., Garner, R. C. & King, M. M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336, 790–792 (1988).
David, S. S., O'Shea, V. L. & Kundu, S. Base-excision repair of oxidative DNA damage. Nature 447, 941–950 (2007).
Nakabeppu, Y. et al. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol. Chem. 387, 373–379 (2006).
Cleaver, J. E., Lam, E. T. & Revet, I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nature Rev. Genet. 10, 756–768 (2009).
Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196–207 (2010).
Lieber, M. R. NHEJ and its backup pathways in chromosomal translocations. Nature Struct. Mol. Biol. 17, 393–395 (2010).
Jiricny, J. The multifaceted mismatch-repair system. Nature Rev. Mol. Cell Biol 7, 335–346 (2006).
Artandi, S. E. & DePinho, R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9–18 (2010).
Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
Bell, O., Tiwari, V. K., Thoma, N. H. & Schubeler, D. Determinants and dynamics of genome accessibility. Nature Rev. Genet. 12, 554–564 (2011).
Warmerdam, D. O. & Kanaar, R. Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat. Res. 704, 2–11 (2010).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355 (2008). References 18 and 19 describes how oncogenes are able to induce the DDR early in oncogenesis.
Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814–819 (2004).
Banerjee, S., Kaye, S. B. & Ashworth, A. Making the best of PARP inhibitors inovarian cancer. Nature Rev. Clin. Oncol. 7, 508–519 (2010).
Friboulet, L. et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin. Cancer Res. 17, 5562–5572 (2011).
Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev. Neurol. 6, 39–51 (2010).
Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421–433 (2010).
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293–301 (2010).
Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515–523 (2007).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005). References 27 and 28 describe the synthetic lethal interaction between BRCA mutations and PARP inhibition.
Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363–369 (2008).
Dobzhansky, T. Genetics of natural populations. Xiii. Recombination and variability in populations of drosophila pseudoobscura . Genetics 31, 269–290 (1946).
Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster . Genetics 59, 37–44 (1968).
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).
Kaelin, W. G. Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1, 99 (2009).
Issaeva, N. et al. 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268–6276 (2010).
Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235–248 (2010).
Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71, 1836–1848 (2011).
Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 . EMBO Mol. Med. 1, 323–337 (2009).
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009). This article describes the results of the first clinical trial to demonstrate the clinical potential of a synthetic lethal approach for therapy.
Balmaña, J., Domchek, S. M., Tutt, A. & Garber, J. E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 1, 29–34 (2011).
Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. & Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705–714 (1995).
Liu, X. et al. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. advance ahead of print http://dx.doi.org/10.1158/1078-0432.CCR-11-1973 (29 November 2011).
McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
Peasland, A. et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372–381 (2011).
Murai, J. et al. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol. Cell. Biol. 31, 2462–2469 (2011).
Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210–220 (2011).
Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Med. 17, 875–882 (2011).
Akamatsu, Y. & Jasin, M. Role for the mammalian Swi5−Sfr1 complex in DNA strand break repair through homologous recombination. PLoS Genet. 6, e1001160 (2010).
Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).
Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011). An important paper suggesting that ETS gene fusions may confer PARP-inhibitor sensitivity in prostate cancer.
Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008). References 50 and 51 are the first demonstrations of synthetic lethal resistance to PARP inhibitors and platinum drugs in BRCA -mutant cells.
Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381–6386 (2009).
Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581–2586 (2008).
Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011).
Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008).
Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA- mutated breast cancers. Nature Struct. Mol. Biol. 17, 688–695 (2010).
Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010).
Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895–1909 (2009).
Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935–939 (2009).
Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736 (2009). This paper provides proof of the concept that targeting additional elements of the DDR and replication machinery, such as neddylation complexes, could provide an alternative approach to cancer therapy.
Lansdorp, P. M. Immortal strands? Give me a break. Cell 129, 1244–1247 (2007).
Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009).
Zhang, M., Atkinson, R. L. & Rosen, J. M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl Acad. Sci. USA 107, 3522–3527 (2010).
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756–760 (2006).
Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A. & Brunner, T. B. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta 1-integrin signaling. Cancer Res. 71, 3453–3458 (2011).
Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011).
Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005–1010 (2009).
Barber, L. J. et al. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS ONE 6, e21639 (2011).
Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159–6168 (2010).
Polo, S. E. & Jackson, S. P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 25, 409–433 (2011).
Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366–374 (2001).
Liu, P. et al. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell 146, 889–903 (2011).
We thank Cancer Research UK, The Wellcome Trust, Breakthrough Breast Cancer, AACR, The Komen Foundation, The Breast Cancer Research Foundation, the European Union and The Breast Cancer Campaign for funding the work in our laboratory. We also acknowledge NHS funding to the Royal Marsden Hospital NIHR Biomedical Research Centre.
C.J.L. and A.A. are named inventors on patents describing the use of PARP inhibitors and may stand to gain under the ICR, 'Rewards to Inventors Scheme'.
Reprints and permissions information is available at www.nature.com/reprints.
About this article
Cite this article
Lord, C., Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287–294 (2012). https://doi.org/10.1038/nature10760
A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications
BMC Bioinformatics (2021)
Cancer Cell International (2021)
Radiation Oncology (2021)
Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2
Cell Death & Disease (2021)
CtBP1/2 differentially regulate genomic stability and DNA repair pathway in high-grade serous ovarian cancer cell